CDC reports on COVID-19 oral antiviral equity, benefits

Advertisements

CDC reports on COVID-19 oral antiviral equity, benefits
hnesich_drupal
Jun 21, 2022

More than 1 million prescriptions for the COVID-19 antiviral pills Lagevrio and Paxlovid were dispensed between late December 2021 and May 2022, but dispensing rates were lowest in the most socially and economically disadvantaged communities, according to a study released today by the Centers for Disease Control and Prevention. In a separate study of electronic health records from Kaiser Permanente Southern California over the period, fewer than 1% of patients aged 12 and older who received Paxlovid to treat mild-to-moderate COVID-19 had a COVID-19-related hospitalization or emergency department visit in the next five to 15 days. CDC said the studies “highlight the importance of ensuring access to oral antiviral medicine in treating COVID-19, a key strategy in preventing hospitalization and death.”

Headline
Advertisements
Shopping Cart
Generated by Feedzy
error: Content is protected !!
Share via
Copy link
Powered by Social Snap